In this study, we investigated the expression of VISTA, a novel immune checkpoint, and its interplay with other key immune regulatory markers, including CD244, CD48, FOXD3, and PVRL2, in pediatric B-ALL patients. Here, FOXD3 is linked to precursor B-cell acute lymphoblastic leukemia.